Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened Venetoclax Duration in Elderly/Frail AML Patients Treated With Azacitidine Plus Venetoclax
NCT07407660Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07407660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407660.